Plain English Summary
Background and study aims
Malaria in Indonesia is a substantial problem with approximately 35% of the population at risk and 10-14% of pregnant women being infected with malaria at any time. Pregnant women are a vulnerable group and both P.falciparum and P.vivax infections contribute to adverse effects of malaria in pregnancy. If you contract malaria during your pregnancy you can have devastating consequences resulting in fever which may trigger preterm labour or pregnancy loss. It is also possible for you to be infected without showing any outward signs or symptoms of malaria, yet if these infections are undetected and left untreated, they can cause anaemia in the mother and can interfere with the growth of the fetus leading to low birth weight, which increases the risk of babies dying during infancy.
Who can participate?
Women between 16-30 weeks of gestation with a viable pregnancy at antenatal visit and residing in the study area will be eligible to join the study.
What does the study involve?
The study will use three intervention methods to assess whether malaria infections in pregnancy and adverse effects associated with it can be reduced. One intervention will provide malaria testing to women with or without the symptoms of malaria at every scheduled antenatal visit. A rapid diagnostic test (RDT) will be used. The RDT is simple to perform, uses a single drop of blood and gives results within 15 minutes. If you test positive for malaria you will be treated with an artemisinin combination drug called dihydroartemisinin-piperaquine (DHP), which is the treatment of choice in the 2nd and 3rd trimester of pregnancy in Indonesia. This method is called intermittent screening and treatment for prevention of malaria in pregnancy (ISTp). A second method called intermittent preventive treatment (IPTp), which is used in most countries in Africa but not yet in Asia, will also be tested. With this method pregnant women regardless of malaria symptoms will be selected to receive the same drug but without prior blood testing. These new methods will be compared with the existing policy in Indonesia, where all pregnant women are tested for malaria at the first antenatal visit only, and those with a positive result are treated with DHP in second and third trimester and with quinine in first trimester. During subsequent antenatal visits, women are tested only if they have symptoms of malaria such as fever. This means that some infections will go undetected. It is anticipated that the two new methods will either detect infections much earlier than the current approach, or prevent malaria altogether.
What are the possible benefits and risks of participating?
DHP is a very effective treatment for malaria in pregnancy. Experience in previous studies of more than 1200 pregnancies treated with DHP in second and third trimester found it a safe drug for the baby. However we will carefully monitor all babies born to the women in the study to see if the drug has any adverse effect on the pregnant or her baby. The findings of this study, together with an assessment of feasibility and cost effectiveness of each of the method stated above, will be used to inform malaria prevention policy for pregnant women in Indonesia and other parts of South East Asia. Those participating in the study will be tested for anaemia and malaria and receive free treatment for these conditions. Transport cost to attend antenatal care will be provided and every woman will receive a long lasting insecticide treated bed net at the time of enrolment. Participants will be followed from recruitment until 8 weeks after delivery.
Where is the study run from?
Women attending routine antenatal care in the community health facilities (Puskesmas) and community integrated health services (Posyandu) under the selected health facilities in SW Sumba and Timika in eastern Indonesia will be recruited. The Eijkman Institute for Molecular Biology (EI) in Jakarta will coordinate the trial and Liverpool School of Tropical Medicine (LSTM) is the Sponsor.
When is the study starting and how long is it expected to run for?
May 2013 to December 2016
Who is funding the study?
The trial is funded by the Medical Research Council (MRC)/Wellcome Trust/Department for International Development (DFID), under the Global Trial Health Schemes, UK
Who is the main contact?
Professor Feiko ter Kuile
terkuile@liv.ac.uk
Trial website
Contact information
Type
Scientific
Primary contact
Prof Feiko ter Kuile
ORCID ID
Contact details
Liverpool School of Tropical Medicine
Malaria Epidemiology unit
Liverpool
L3 5QA
United Kingdom
Type
Scientific
Additional contact
Dr Rukhsana Ahmed
ORCID ID
Contact details
Liverpool School of Tropical Medicine
Pembroke Place
Liverpool
L3 5QA
United Kingdom
-
Rukhsana.Ahmed@lstmed.ac.uk
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
Version 1.0
Study information
Scientific title
Intermittent Screening and Treatment Or intermittent Preventing therapy for the control of Malaria in Pregnancy in Indonesia: an open label cluster randomised controlled superiority trial
Acronym
STOPMiP
Study hypothesis
Among pregnant women protected with long lasting insecticide treated bed nets (LLITNs), intermittent screening with rapid diagnostic tests (RDTs) at Antenatal care (ANC) visits provided at least 3 or more times during pregnancy and treatment of RDT positive women with dihydroartemisinin-piperaquine (ISTp-DHP), or intermittent preventive treatment with dihydroartemisinin-piperaquine (IPTp-DHP) is more efficacious than single screening and treatment (SSTp-DHP) in preventing malaria in pregnancy in an area of relatively low prevalence of P. falciparum and P. vivax.
Ethics approval
1. Liverpool School of Tropical Medicine, 16/10/2012, Research Protocol ref: 12.28
2. London School of Hygiene and Tropical Medicine, 03/01/2013, ref: 6325
3. Eijkman Institute for Molecular Biology, Jakarta, 20/02/2013, ref: Project N: 57
4. Litbangkes, Ministry of Health, Jakarta (NIH), 01/03/2013, ref: LB02.01/5.2/KE059/2013
Study design
Open-label three-arm parallel-group cluster randomised superiority trial
Primary study design
Interventional
Secondary study design
Cluster randomised trial
Trial setting
Other
Trial type
Treatment
Patient information sheet
Not available in web format, please use the contact details to request a patient information sheet
Condition
Malaria in pregnancy
Intervention
SSTp-DHP: (control group): Participants in the 2nd or 3rd trimester will be screened with HRP2-pLDH combination RDT (Pf/Pan First Response®, Premier Medical Corporation Ltd, India) at 1st antenatal visit (booking visit) and RDT-positive women will receive treatment with DHP. In subsequent visits only women with symptoms of malaria will be tested with RDT. This is the usual care in Indonesia.
ISTp-DHP: Women in their 2nd-3rd trimester attending scheduled antenatal care will receive screening at each visit regardless of malaria symptoms with the study RDT and RDT positive women will receive treatment with DHP.
IPTp-DHP: Intermittent preventive treatment with DHP provided at least one month apart in 2nd-3rd trimester women attending for scheduled antenatal care.
Intervention type
Drug
Phase
Not Applicable
Drug names
Dihydroartemisinin-piperaquine (ISTp-DHP), dihydroartemisinin-piperaquine
Primary outcome measures
Malaria infection at delivery (peripheral and or placental) detected by RDT, microscopy or polymerase chain reaction (PCR), or placental Histology (active) measured at the time when women deliver, except incidence of malaria which will occur anytime between enrolment and delivery when and if they are positive for malaria.
Secondary outcome measures
Efficacy
Individual components of composite primary outcome
1. Incidence of malaria infection by species measured by PCR (using dried blood spots)
2. Congenital malaria, defined as parasitaemia in cord or newborn peripheral blood in the first seven days of life detected by smear, RDT or PCR.
3. Composite of spontaneous births resulting in either low birth weight, preterm birth
4. Mean and Low birth weight
5. Mean Gestational age at birth, Preterm delivery (< 37 weeks) measured by using Ballard score
6. Small for gestational age (<10th percentile of WHO recommended reference)
7. Mean maternal haemoglobin and anaemia at 36 weeks and at delivery measured using HemoCue reading
8. Incidence all-cause and malaria clinic visits
9. Cord haemoglobin (Hb) and newborn anaemia
10. Neonatal deaths
11. Perinatal death
Tolerability and safety
1. Serious adverse events & adverse events
2. Congenital malformations in the newborn identified at birth and by 6 weeks afterbirth.
Overall trial start date
15/05/2013
Overall trial end date
26/11/2016
Reason abandoned
Eligibility
Participant inclusion criteria
Pregnant women of any age and gravidity with:
1. Gestational age 16 to 30 weeks (inclusive) by last menstrual period (LMP) (if available) or fundal height or after quickening
2. Viable pregnancy (fetal heart sound detected, or other signs of fetal life such as perceived motion of fetus)
3. Willing to participate and complete the study schedule
4. Has provided written informed consent
5. Resident of study area and intending to stay in the area for the duration of the follow-up
6. Willing to give birth in a study selected health facility (Puskesmas, Polindes or hospital)
Participant type
Patient
Age group
Adult
Gender
Female
Target number of participants
2279 pregnant women
Participant exclusion criteria
1. Residence outside study area or planning to move out in the 6 months following enrolment
2. Pre-existing conditions likely to cause complication in the current pregnancy (e.g. hypertension, diabetes, asthma, renal disease, liver disease, any spinal deformity)
3. Known allergy or previous adverse reaction to any of the study drugs based on information provided by the participant such as development of skin rash, severe nausea and vomiting
4. Requires cotrimoxazole prophylaxis for opportunistic infection (e.g. for women known to be HIV positive)
5. Treatment with antimalarials in the last month ( e.g mefloquine, halofantrine, lumafantrine, chloroquine) or last week ( quinine)
6. Unable to give informed consent (for example due to mental disability)
7. Severe malaria according to WHO definition requiring parenteral treatment
8. Family history of sudden death or of congenital prolongation of QTc interval, or known congenital prolongation of the QTc-interval or any known cardiac condition, such as history of symptomatic cardiac arrhythmia, bradycardia or congestive heart failure
9. Taking medicinal products that are known to prolong QTc interval
Recruitment start date
16/05/2013
Recruitment end date
21/04/2016
Locations
Countries of recruitment
Indonesia
Trial participating centre
Liverpool School of Tropical Medicine
Liverpool
L3 5QA
United Kingdom
Funders
Funder type
Charity
Funder name
Medical Research Council (MRC) (UK)
Alternative name(s)
MRC
Funding Body Type
government organisation
Funding Body Subtype
Federal/National Government
Location
United Kingdom
Funder name
Wellcome Trust (UK), grant ref: : 096476
Alternative name(s)
Wellcome
Funding Body Type
private sector organisation
Funding Body Subtype
international
Location
United Kingdom
Funder name
Department for International Development (DFID) (UK), ref: JGHT 165
Alternative name(s)
Department for International Development, UK, DFID
Funding Body Type
government organisation
Funding Body Subtype
Federal/National Government
Location
United Kingdom
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Results - basic reporting
Publication summary